Novavax to Host Conference Call to Discuss First Quarter Financial Results and Operational Highlights on May 10, 2021
Novavax, Inc. (Nasdaq: NVAX) will report its Q1 2021 financial results and operational highlights on May 10, 2021, after U.S. market close. A conference call will occur at 4:30 p.m. ET, with dial-in options available for domestic and international participants. Details for the call, including replay options starting May 10 at 7:30 p.m. ET, are provided in the press release. Novavax is advancing its COVID-19 vaccine candidate and its quadrivalent influenza vaccine towards regulatory submission, utilizing its proprietary technology to address global health needs.
- Novavax is advancing NVX-CoV2373 for COVID-19 toward regulatory submission.
- The quadrivalent influenza vaccine, NanoFlu™, met all primary objectives in its Phase 3 trial.
- None.
GAITHERSBURG, Md., April 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its first quarter 2021 financial results and operational highlights on Monday, May 10, 2021, following the close of U.S. financial markets. Details of the event and replay are as follows:
Conference call details: | ||
Date: | May 10, 2021 | |
Time: | 4:30 p.m. U.S. Eastern Time (ET) | |
Dial-in number: | (866) 652-5200 (Domestic) or (412) 317-6060 (International) | |
Webcast: | ||
• Participants will be prompted to request to join the Novavax, Inc. call. | ||
• To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast. | ||
Replay details: | |
Date: | Available starting at 7:30 p.m. ET, May 10, 2021 |
Dial-in number: | (877) 344-7529 (Domestic) or (412) 317-0088 (International) |
Passcode: | 10155684 |
Webcast: | www.novavax.com/events, until August 10, 2021 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com
Solebury Trout
Jennifer Porcelli | 646-378-2962
jporcelli@soleburytrout.com
Media
Amy Speak | 617-420-2461
Laura Keenan | 410-419-5755
media@novavax.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-first-quarter-financial-results-and-operational-highlights-on-may-10-2021-301276159.html
SOURCE Novavax, Inc.
FAQ
When will Novavax report its Q1 2021 financial results?
What time is the Novavax conference call?
How can I access the replay of Novavax's conference call?
What is NVX-CoV2373?
What are the key vaccine candidates from Novavax?
